Comparative Pharmacology
Head-to-head clinical analysis: SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH versus TINDAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH versus TINDAMAX.
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH vs TINDAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis. Together, they provide sequential blockade of folate metabolism, leading to bactericidal activity.
Tindamax (tinidazole) is a nitroimidazole antibiotic that enters bacterial and protozoal cells, where the nitro group is reduced by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It exhibits activity against anaerobic bacteria and protozoa.
1 double-strength tablet (800 mg sulfamethoxazole/160 mg trimethoprim) orally every 12 hours for most infections; single-strength tablet (400 mg/80 mg) is used for prophylaxis: 1 tablet orally daily.
100 mg intravenously every 8 hours over 60 minutes.
None Documented
None Documented
Sulfamethoxazole: 10-12 hours (prolonged in renal impairment); Trimethoprim: 8-11 hours (prolonged in hepatic impairment).
Terminal elimination half-life is 4-6 hours; prolonged to 10-12 hours in severe renal impairment (CrCl <30 mL/min).
Sulfamethoxazole: primarily renal (70-90% as unchanged drug and acetylated metabolite); Trimethoprim: renal (50-60% unchanged, rest as metabolites); small biliary/fecal elimination (<5% each).
Primarily renal excretion (70-80% as unchanged drug) with 10-15% fecal elimination via biliary secretion.
Category D/X
Category C
Antibiotic
Antibiotic